Stents with vitronectin receptor antagonists against restenosis

• US 20040236413A1
• Filed: 06/28/2004
• Published: 11/25/2004
• Est. Priority Date: 07/19/2001
• Status: Abandoned Application

• Current Assignee: Bayer Healthcare AG (Bayer AG)
• Original Assignee: Bayer Healthcare AG (Bayer AG)
• Inventors: Urbahns, Klaus, Low, Jeffrey, Gelfert-Peukert, Sabine, Kalbe, Jochen, Gerdes, Christoph, Zuleger, Susanne
• Application Number:
  US10/484,414
• Publication Number:
  US 20040236413A1
• Time in Patent Office: Days
• US Class Current: 623/1.42
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/436 of receptors
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The application relates to vitronectin receptor antagonist-containing stents and to their production and use.

Claims

1. A stent comprising one or more vitronectin receptor antagonists.

3. The stent according to claim 1, further comprising an additional membrane coating.

4. The stent according to claim 1, 2, or 3, comprising at least one further active ingredient.

12. A method for the prophylaxis or therapy of restenosis through use of a stent according to claim 1, 2, 3, or 4, in combination with local and/or systemic administration of at least one other active ingredient suitable for the prophylaxis or therapy of restenosis.

13. A method for the prophylaxis or therapy of restenosis comprising using a stent according to claim 1, 2, 3, or 4 in combination with systemic administration of a vitronectin receptor antagonist.

2. A stent for treatment of restenosis following PCTA, comprising one or more vitronectin receptor antagonists.

5. A method for the treatment or prevention of reocclusion in restenotic arteries comprising using a vitronectin receptor antagonist-containing stent.

6. A process for production of stents comprising using one or more vitronectin receptor antagonists in the production process.

7. A process for the production of stents, characterized in that stents are coated or filled with one or more vitronectin receptor antagonists.

8. A process for the production of stents, characterized in that a polymeric carrier composition comprising one or more vitronectin receptor antagonists is shaped into a stent.

9. A method for the treatment of patients with restenotic arteries comprising using simultaneously one or more vitronectin receptor antagonists and a stent.

10. The method according to claim 9, characterized in that one or more vitronectin receptor antagonists are present in or on the stent and are released locally.

11. A process for production of stents for the treatment or prevention of restenosis, comprising using one or more vitronectin receptor antagonists in the production process.